Holen Sie sich die Stockscreener-App
0.1697
9.59%
-0.018
Handel nachbörslich:
.17
0.0003
+0.18%
Schlusskurs vom Vortag:
$0.1877
Offen:
$0.19
24-Stunden-Volumen:
3.05M
Relative Volume:
0.17
Marktkapitalisierung:
$8.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.53M
KGV:
-0.0352
EPS:
-4.82
Netto-Cashflow:
$-11.12M
1W Leistung:
-19.80%
1M Leistung:
-26.54%
6M Leistung:
-65.39%
1J Leistung:
-87.79%
1-Tages-Spanne:
$0.1601
$0.1932
1-Wochen-Bereich:
$0.1601
$0.2044
52-Wochen-Spanne:
$0.15
$1.50
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Firmenname
Processa Pharmaceuticals Inc
Sektor
Branche
Telefon
443-776-3133
Adresse
601 21ST STREET, SUITE 300, VERO BEACH
Vergleichen Sie PCSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.1697 | 9.47M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-25 | Eingeleitet | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Aktie (PCSA) Neueste Nachrichten
Applying Elliott Wave Theory to Processa Pharmaceuticals Inc.July 2025 Catalysts & Entry and Exit Point Strategies - Newser
Is now the right time to enter Processa Pharmaceuticals Inc.Earnings Miss & Precise Entry and Exit Recommendations - khodrobank.com
Will Processa Pharmaceuticals Inc. price bounce be sustainableQuarterly Market Review & Trade Opportunity Analysis - Newser
Historical volatility pattern of Processa Pharmaceuticals Inc. visualizedTrade Risk Summary & Safe Entry Zone Identification - Newser
Combining machine learning predictions for Processa Pharmaceuticals Inc.Dollar Strength & AI Powered Market Entry Ideas - Newser
Dow Update: What drives Processa Pharmaceuticals Inc.’s stock price2025 Key Highlights & Scalable Portfolio Growth Methods - khodrobank.com
Institutional scanner results for Processa Pharmaceuticals Inc.2025 Macro Impact & Consistent Income Trade Ideas - Newser
Full technical analysis of Processa Pharmaceuticals Inc. stockPortfolio Risk Summary & Safe Capital Allocation Plans - Newser
Will Processa Pharmaceuticals Inc. benefit from green energy policies2025 Earnings Impact & Growth Focused Investment Plans - khodrobank.com
Is Processa Pharmaceuticals Inc.’s ROE strong enoughJuly 2025 Macro Moves & AI Driven Price Predictions - khodrobank.com
What Fibonacci levels say about Processa Pharmaceuticals Inc. reboundStop Loss & Verified Momentum Stock Watchlist - Newser
Is Processa Pharmaceuticals Inc. stock poised for growth2025 Valuation Update & Long Hold Capital Preservation Tips - Newser
How to forecast Processa Pharmaceuticals Inc. trends using time seriesQuarterly Trade Review & Free Accurate Trade Setup Notifications - Newser
Published on: 2025-09-03 03:51:14 - Newser
Can Processa Pharmaceuticals Inc. maintain its current growth rate2025 Historical Comparison & AI Forecast Swing Trade Picks - khodrobank.com
What’s the recovery path for long term holders of Processa Pharmaceuticals Inc.Bond Market & Technical Pattern Alert System - Newser
Sentiment analysis tools applied to Processa Pharmaceuticals Inc.Market Movers & Safe Entry Trade Reports - Newser
Exit strategy if you’re trapped in Processa Pharmaceuticals Inc. - Newser
Analyzing drawdowns of Processa Pharmaceuticals Inc. with statistical toolsWeekly Gains Report & Weekly Setup with High ROI Potential - Newser
Processa Pharmaceuticals Inc. stock retracement – recovery analysisMarket Risk Analysis & Weekly Watchlist of Top Performers - Newser
Processa Pharmaceuticals Adjourns Special Shareholder Meeting - TipRanks
Can Processa Pharmaceuticals Inc. sustain its profitability2025 Market WrapUp & AI Driven Stock Movement Reports - khodrobank.com
Does Processa Pharmaceuticals Inc. meet Warren Buffett’s criteriaWeekly Earnings Recap & Free Accurate Trade Setup Notifications - khodrobank.com
Can Processa Pharmaceuticals Inc. sustain earnings growthSwing Trade & Free AI Powered Buy and Sell Recommendations - khodrobank.com
Published on: 2025-08-31 19:29:49 - Newser
Real time breakdown of Processa Pharmaceuticals Inc. stock performanceJuly 2025 Levels & Real-Time Stock Movement Alerts - Newser
Backtesting results for Processa Pharmaceuticals Inc. trading strategiesWatch List & Safe Entry Point Identification - Newser
How Processa Pharmaceuticals Inc. stock performs during market volatilityWeekly Gains Summary & Weekly Breakout Stock Alerts - Newser
Processa Pharmaceuticals Inc. Reaches Critical Trendline Support2025 Volume Leaders & Growth Oriented Trade Recommendations - beatles.ru
Can momentum traders help lift Processa Pharmaceuticals Inc.Earnings Risk Report & Weekly Watchlist for Consistent Profits - Newser
Using Python tools to backtest Processa Pharmaceuticals Inc. strategiesMarket Growth Summary & AI Forecast for Swing Trade Picks - Newser
How hedge fund analytics apply to Processa Pharmaceuticals Inc. stockWeekly Gains Report & Daily Profit Focused Screening - Newser
Short Interest Drops in Processa Pharmaceuticals Inc. After RallyQuarterly Trade Summary & AI Powered Market Trend Analysis - beatles.ru
Is Processa Pharmaceuticals Inc. a candidate for recovery playQuarterly Earnings Report & Low Risk High Reward Trade Ideas - Newser
Finanzdaten der Processa Pharmaceuticals Inc-Aktie (PCSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Processa Pharmaceuticals Inc-Aktie (PCSA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jan 27 '25 |
Buy |
0.80 |
87,200 |
69,542 |
87,200 |
| Young David | Pres. Research & Development |
Jan 27 '25 |
Buy |
0.80 |
124,500 |
99,289 |
205,405 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 27 '25 |
Buy |
0.80 |
43,500 |
34,691 |
43,500 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):